Particle release in extracorporeal low-density lipoprotein lowering therapies.
Release of microparticles into the blood during extracorporeal circulation must be kept low because of possibly serious acute and chronic adverse effects. Concentration and size distribution of microparticles were measured during simulated treatments (n = 7) on original equipment for 2 standard low-density lipoprotein (LDL) elimination procedures (DALI 750, Fresenius AG, St. Wendel, Germany and Liposorber, Kaneka Corporation, Osaka, Japan) and compared to hemofiltration solutions. For both systems as well as in hemofiltration solutions, the mean particle concentrations in 500 ml portions gathered from the efferent blood line stayed below 10% of pharmacopoeia standards for infusion solutions (United States Pharmacopoeia, European Pharmacopoeia) in all measured size classes. Although particle concentrations were comparable in all systems, the mean total number of particles > or =2 microm released per session was lowest in the DALI (167,000) compared to the Liposorber (465,000) and hemofiltration solutions (2,240,000). This was mainly due to different total processed blood volumes necessary to achieve the required LDL reduction.
BioArtProducts GmbH; Dialyse-Gemeinschaft Nord e.V. Rostock, Germany.
K
K
Martins
P
P
Ahrenholz
G B
GB
Matic
D
D
Hofmann
M
M
Tiess
R E
RE
Winkler
W
W
Ramlow
D000327:Adsorption; D001781:Blood Component Removal / Q000592:standards*; D006801:Humans; D008077:Lipoproteins, LDL; D010316:Particle Size; D010602:Pharmacopoeias as Topic / Q000592:standards; D012996:Solutions / Q000592:standards*
D008077:Lipoproteins, LDL; D012996:Solutions